Significance of age and comorbidity on treatment modality, treatment adherence, and prognosis in elderly ovarian cancer patients

Gynecologic Oncology

Volumn 127, Issue 2, 2012, Pages 367-374

  Jorgensen, Trine Lembrecht ^a   Teiblum, Sandra ^b   Paludan, Merete ^c   Poulsen, Laurids Østergaard ^d   Jorgensen, Anni Young Stensgård ^e   Bruun, Karin Herskind ^f   Hallas, Jesper ^g   Herrstedt, Jorn ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d AALBORG UNIVERSITY HOSPITAL   (Denmark)

^e NAESTVED HOSPITAL   (Denmark)

^f Mental Health Services CPH   (Denmark)

^g UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Aged; Chemotherapy; Comorbidity; Elderly; Ovarian cancer; Survival

Indexed keywords

CARBOPLATIN; DOCETAXEL; PACLITAXEL;

AGE; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; COHORT ANALYSIS; COMORBIDITY; CYTOREDUCTIVE SURGERY; DRUG DOSE REDUCTION; FEMALE; GERIATRIC PATIENT; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; OVERALL SURVIVAL; PATIENT COMPLIANCE; PATIENT PARTICIPATION; PERITONEUM CANCER; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL TIME;

ABDOMINAL CAVITY; ADENOCARCINOMA; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRIDGED COMPOUNDS; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; COMORBIDITY; DENMARK; FEMALE; GUIDELINE ADHERENCE; HUMANS; LOGISTIC MODELS; MIDDLE AGED; NEOADJUVANT THERAPY; OVARIAN NEOPLASMS; OVARIECTOMY; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; REGISTRIES; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TAXOIDS;

EID: 84867404675     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.07.001     Document Type: Article

References (34)

1. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman Global cancer statistics CA Cancer J Clin 61 2 2011 69 90
2. G. Engholm, J. Ferlay, N. Christensen, T.B. Johannesen, Å. Klint, and J.E. Kotlum NORDCAN: cancer incidence, mortality, prevalence and survival in the Nordic countries, version 5.1 March 2012 Association of the Nordic Cancer Registries. Danish Cancer Society Available from http://www.ancr.nu, accessed on 7/3/2012
3. J.K. Chan, R. Urban, M.K. Cheung, K. Osann, J.Y. Shin, and A. Husain Ovarian cancer in younger vs older women: a population-based analysis Br J Cancer 95 10 2006 1314 1320
4. D. Pectasides, G. Fountzilas, G. Aravantinos, A. Bamias, H.P. Kalofonos, and D. Skarlos Epithelial ovarian carcinoma in younger vs older women: is age an independent prognostic factor? The Hellenic Oncology Cooperative Group experience Int J Gynecol Cancer 17 5 2007 1003 1010
5. W.E. Winter III, G.L. Maxwell, C. Tian, J.W. Carlson, R.F. Ozols, and P.G. Rose Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study J Clin Oncol 25 24 2007 3621 3627
6. H.A. Maas, R.F. Kruitwagen, V.E. Lemmens, S.H. Goey, and M.L. Janssen-Heijnen The influence of age and co-morbidity on treatment and prognosis of ovarian cancer: a population-based study Gynecol Oncol 97 1 2005 104 109
7. W.P. McGuire, W.J. Hoskins, M.F. Brady, P.R. Kucera, E.E. Partridge, and K.Y. Look Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer N Engl J Med 334 1 1996 1 6
8. M.J. Piccart, K. Bertelsen, K. James, J. Cassidy, C. Mangioni, and E. Simonsen Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results J Natl Cancer Inst 92 9 2000 699 708
9. K. Aabo, M. Adams, P. Adnitt, D.S. Alberts, A. Athanazziou, and V. Barley Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group Br J Cancer 78 11 1998 1479 1487
10. G.C. Stuart, H. Kitchener, M. Bacon, A. duBois, M. Friedlander, and J. Ledermann Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference Int J Gynecol Cancer 21 4 2011 750 755
11. J.P. Neijt, S.A. Engelholm, M.K. Tuxen, P.G. Sorensen, M. Hansen, and C. Sessa Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer J Clin Oncol 18 17 2000 3084 3092
12. R.F. Ozols, B.N. Bundy, B.E. Greer, J.M. Fowler, D. Clarke-Pearson, and R.A. Burger Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study J Clin Oncol 21 17 2003 3194 3200
13. A. du Bois A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer CancerSpectrum Knowl Environ 95 17 2003 1320 1329
14. A.L. Petri, S.K. Kjaer, I.J. Christensen, J. Blaakaer, E. Hogdall, and U. Jeppesen Validation of epithelial ovarian cancer and fallopian tube cancer and ovarian borderline tumor data in the Danish Gynecological Cancer Database Acta Obstet Gynecol Scand 88 5 2009 536 542
15. C.K. Hogdall, M.L.S. Nielsen, and L. Taaning Annual report 2009-2010 - Danish Gynecologic Cancer Database. Nation-wide clinical database of ovarian, uterine, and cervical cancer 2012 Available from http://www.dgc.eu.com
16. M.L. Gjerstorff The Danish Cancer Registry Scand J Public Health 39 7 Suppl. 2011 42 45
17. K. Helweg-Larsen The Danish Register of Causes of Death Scand J Public Health 39 7 Suppl. 2011 26 29
18. M. Saklad Grading of patients for surgical procedures Anesthesiology 2 1941 281 284
19. W.D. Owens, J.A. Felts, and E.L. Spitznagel Jr. ASA physical status classifications: a study of consistency of ratings Anesthesiology 49 4 1978 239 243
20. D.W. Hosmer, and P. Royston Using Aalen's linear hazards model to investigate time-varying effects in the proportional hazards regression model The Stata Journal. 2 4 2002 331 350
21. M. Extermann, and A. Hurria Comprehensive geriatric assessment for older patients with cancer J Clin Oncol 25 14 2007 1824 1831
22. M. Bjerager, T. Palshof, R. Dahl, P. Vedsted, and F. Olesen Delay in diagnosis of lung cancer in general practice Br J Gen Pract 56 2006 863 868
23. C. Bouchardy, E. Rapiti, S. Blagojevic, A.T. Vlastos, and G. Vlastos Older female cancer patients: importance, causes, and consequences of undertreatment J Clin Oncol 25 14 2007 1858 1869
24. T. Susini, G. Amunni, E. Busi, A. Villanucci, C. Carriero, and G. Taddei Ovarian cancer in the elderly: feasibility of surgery and chemotherapy in 89 geriatric patients Int J Gynecol Cancer 17 3 2007 581 588
25. F. Hilpert, A. du Bois, E.R. Greimel, J. Hedderich, G. Krause, and L. Venhoff Feasibility, toxicity and quality of life of first-line chemotherapy with platinum/paclitaxel in elderly patients aged > or = 70 years with advanced ovarian cancer - a study by the AGO OVAR Germany Ann Oncol 18 2 2007 282 287
26. K.N. Moore, M.S. Reid, D.N. Fong, T.K. Myers, L.M. Landrum, and K.M. Moxley Ovarian cancer in the octogenarian: does the paradigm of aggressive cytoreductive surgery and chemotherapy still apply? Gynecol Oncol 110 2 2008 133 139
27. S. Pignata, and S. Monfardini Single agents should be administered in preference to combination chemotherapy for the treatment of patients over 70 years of age with advanced ovarian carcinoma Eur J Cancer 36 7 2000 817 820
28. A.N. Fader, V. von Gruenigen, H. Gibbons, F. Abushahin, D. Starks, and M. Markman Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients Gynecol Oncol 109 1 2008 33 38
29. S. Pignata, E. Breda, G. Scambia, C. Pisano, V. Zagonel, and D. Lorusso A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study Crit Rev Oncol Hematol 66 3 2008 229 236
30. M. Extermann, I. Boler, R.R. Reich, G.H. Lyman, R.H. Brown, and J. Defelice Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score Cancer 118 13 2012 3377 3386
31. A. Hurria, K. Togawa, S.G. Mohile, C. Owusu, H.D. Klepin, and C.P. Gross Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study J Clin Oncol 29 25 2011 3457 3465
32. C. Langstraat, G.D. Aletti, and W.A. Cliby Morbidity, mortality and overall survival in elderly women undergoing primary surgical debulking for ovarian cancer: a delicate balance requiring individualization Gynecol Oncol 123 2 2011 187 191
33. S. Tingulstad Survival and prognostic factors in patients with ovarian cancer Obstet Gynecol 101 5 2003 885 891
34. M.M. Thrall, B.A. Goff, R.G. Symons, D.R. Flum, and H.J. Gray Thirty-day mortality after primary cytoreductive surgery for advanced ovarian cancer in the elderly Obstet Gynecol 118 3 2011 537 547